

SCI PHARMTECH, INC. 旭富製藥科技

簡報

ISO 14001

BUREAU VERITAS
Certification



ISO 9001

BUREAU VERITAS
Certification



公司概況Profile



員工數Employee : 205

設立日期：中華民國七十六年九月十八日

Date of establishment: Sep. 18, 1987

資本額Capital：新台幣662佰萬元(NTD 662mn)

營業項目Business：

原料藥API (40.96%)

中間體Intermediate (46.82%)

特用化學品 Custom-made chemicals (12.22%)

公司概況 Outline

	Y2012	Y2013
歐洲Europe	41.74%	36.01%
美洲America	22.11%	22.80%
亞洲Asia	18.15%	24.00%
國內Taiwan	18.00%	17.19%
合計Total	100.00%	100.00%

製藥產業的上、中、下游 SCI's position

上游
Upstream

基本原料 RM



中間體 Intermediate:
生產原料藥之
中間步驟所產出之產品 Products before API



中游
Midstream

原料藥 API:
製劑中之有效成分 Treatable ingredient



下游

Downstream

製劑: 成品藥 Formulation

旭富營業範圍
SCI's businesses

營運概況-IS

Unit: K NTD

	2013	2014 Jan.-Feb.
營收Sales	1,292,734	258,462
營業成本COGS	(895,753)	(159,014)
毛利Gross Profit	396,981	99,448
毛利率 GP Ratio	30.7%	38.5%
營業費用Operating Expenses	(191,122)	(37,363)
營業利益Operating Income	205,859	62,085
營業外損益Non-Operating In/Ex	(12,079)	(783)
稅前淨利 Net Profit before Tax	193,780	61,302
所得稅Income Tax	(33,842)	
本期淨利Net Profit after Tax	159,938	

產品組合-Products

Y2011	%	Y2012	%	Y2013	%	Amount
Di-VaNa	24.51%	V.A.	18.66%	PGA	18.31%	236,686,252
PGA	17.65%	PGA	16.61%	Di-VaNa	16.92%	218,774,251
V.A.	13.76%	Di-VaNa	15.97%	S20/38	8.39%	108,535,706
PPON	10.70%	PPON	7.88%	V.A.	8.23%	106,358,818
M85	5.25%	Pent-2	4.78%	LPF.Na	6.58%	85,006,881
Pent-2	3.73%	5-HMT	4.33%	PPON	6.53%	84,401,669
DBS	3.08%	M85	3.89%	5-HMT	4.51%	58,335,737
M115	2.55%	DBS	2.73%	PEB.Na	3.98%	51,426,485
M74	2.31%	M115	2.59%	NaVa	3.34%	43,215,002
NBE	1.87%	M74	2.18%	DBS	2.63%	33,956,773
Total	85.40%	Total	79.62%	Total	79.42%	


No.	Product	%	Sales (NT\$)
1	S20/38	20.70%	53,490,521
2	PGA	14.77%	38,162,489
3	Di-VaNa	7.41%	19,152,944
4	DBS	6.35%	16,399,912
5	Pent-2	5.49%	14,179,200
6	NaVa	5.03%	12,992,192
7	DBPR	4.71%	12,173,333
8	Chiral-auxiliary	4.33%	11,198,528
9	S-MMAA	3.57%	9,230,788
10	NBE	3.33%	8,596,189

產品介紹Products



產品介紹Product

- Divalproex Sodium (Di-Va)




- ✓ 學名藥於2009推出
- ✓ 12個客戶

Generic came out in 2009
12 customers

產品介紹Product

Valproic Acid (VA)




✓ 20個客戶

20 customers

產品介紹Product

● Pyrogallolaldehyde (PGA) - Benserazide



✓治療帕金森氏症之中間體


Intermediate for Parkinson's Disease

✓2個客戶

2 customers

產品介紹Product

Pentobarbital Sodium



- ✓ 鎮定安眠用之原料藥
- ✓ 4個客戶


API used as calmative
4 customers

產品介紹Product

Anti-inflammatory (Loxoprofen sodium)


- ✓ 2012年銷售5佰萬 5 mn sales in 2012.
- ✓ 2013年銷售85佰萬 85 mn sales in 2013
- ✓ 日本市場200-300公噸,200美金/公斤
Japan market:200-300MT at USD 200/kg

S20/38



產品介紹Product

5-HMT – Ritonavir, Lopinavir



✓ 愛滋病藥物之中間體

For AIDS treatment

產品介紹Product

Antidepressant (Duloxetine)

- ✓ 2013年底專利到期 Patent expired in the end of 2013
- ✓ 10個客戶 10 customers
- ✓ 中間體為S-MMAA(Intermediate)
- ✓ 近三年營業額約1仟萬 close to 10 mn sales over 3 years

Lorcaserin

產品介紹Product

- ✓ Cyclophosphamide: 高效能原料藥
- Cyclophosphamide: high-potent API



GMP Status(GMP現況)

<i>API</i>	<i>CGMP certified (TFDA)</i>	<i>CEP (EDQM)</i>	<i>DMF (USA)</i>	<i>MF (Japan)</i>	<i>DMF (Canada)</i>
Valproic Acid (*)	2003	2004	2003	2008	2008
Allopurinol	2004	2003	2011		
Probucol	2004		2004		
Sodium Valproate	2004	2006			
Divalproex Sodium (**)	2005		2005		2010
Bisoprolol Fumarate	2006				
Pentobarbital Sodium	2009	2011			
Propafenone Hydrochloride	2010	2012	2010	2012	2012
Methylphenidate HCl	2011				
Duloxetine Hydrochloride	2012		2010/2011		
Thiopental acid	2012				
Loxoprofen Sodium Hydrate	2012			2011	
Articaine Hydrochloride	2013				
Clindamycin Palmitate HCl			2011		
Cyclophosphamide			2012		

簡報完畢



敬請指教